Concord Drugs Issues Corrigendum on Q3FY26 Results for Labour Codes Disclosure
Concord Drugs Limited submitted its Q3FY26 auditor's review report and subsequently issued a corrigendum addressing Labour Codes implementation details. The company's subsidiary Proton Remedies reported revenue of ₹124.83 lakhs and net profit of ₹1.17 lakhs for nine months, while the company raised ₹13,36,29,375 through preferential issues in November 2025.
*this image is generated using AI for illustrative purposes only.
Concord Drugs Limited has submitted its Independent Auditor's Review Report on both consolidated and standalone unaudited quarterly and year-to-date financial results for the quarter ended December 31, 2025. The review was conducted by Pundarikashyam and Associates, Chartered Accountants, in compliance with SEBI Regulation 33.
Corrigendum to Financial Results
The company issued a corrigendum on February 16, 2026, addressing an inadvertent omission in its original Q3FY26 financial results disclosure submitted on February 14, 2026. The update specifically relates to the complete implementation details of Labour Codes that were not fully reflected in the initial disclosure.
| Parameter | Details |
|---|---|
| Corrigendum Date | February 16, 2026 |
| Original Disclosure Date | February 14, 2026 |
| Subject | Labour Codes Implementation |
| Regulation | SEBI Regulation 30 |
Labour Codes Implementation Update
The corrected disclosure provides comprehensive details about the Government of India's consolidation of 29 existing labour legislations into four unified Labour Codes. These codes became effective from November 21, 2025, though supporting rules are yet to be notified.
| Code Type | Details |
|---|---|
| Code on Wages | 2019 |
| Code on Social Security | 2020 |
| Industrial Relation Code | 2020 |
| Occupational Safety Code | 2020 |
| Effective Date | November 21, 2025 |
Auditor Review Details
The independent auditor's review was conducted for both consolidated and standalone financial results covering the quarter ended December 31, 2025, and year-to-date results from April 1, 2025, to December 31, 2025.
| Parameter | Details |
|---|---|
| Auditing Firm | Pundarikashyam and Associates |
| FRN | 0113305S |
| Partner | B. Surya Prakasa Rao |
| Member Number | 205125 |
| Review Date | February 14, 2026 |
| UDIN | 26205125CIYFWP4289 |
Subsidiary Performance
The consolidated results include performance from subsidiary Proton Remedies Private Limited. The subsidiary's financial contribution for the nine-month period shows steady operational performance.
| Metric | Amount |
|---|---|
| Total Revenue | ₹124.83 lakhs |
| Net Profit After Tax | ₹1.17 lakhs |
| Period | Nine months ended December 31, 2025 |
Fund Raising and Utilization
The company disclosed details of its recent preferential issue and confirmed no deviation in fund utilization. The fundraising was completed in November 2025 with proper regulatory compliance.
| Parameter | Details |
|---|---|
| Mode of Fund Raising | Preferential Issues |
| Date of Raising Funds | November 20, 2025 |
| Amount Raised | ₹13,36,29,375 |
| Deviation in Fund Use | No |
| Audit Committee Comments | NIL |
Regulatory Compliance
The auditor confirmed that the financial statements comply with Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting and SEBI regulations. The company reported no outstanding defaults on loans and debt securities for the quarter ended December 31, 2025. The company continues to monitor the finalisation of Central and State Rules and clarifications from the Government regarding other aspects of the New Labour Code, having estimated and accounted for incremental liability for employees which is not material to the financial results.
Historical Stock Returns for Concord Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.58% | -3.41% | -14.25% | -17.47% | +5.90% | 0.0% |
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
